| Year |
Citation |
Score |
| 2020 |
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, ... ... Hagenbeek A, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica. PMID 32273476 DOI: 10.3324/Haematol.2019.243238 |
0.405 |
|
| 2019 |
Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, ... ... Hagenbeek A, et al. Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900743. PMID 31498031 DOI: 10.1200/Jco.19.00743 |
0.336 |
|
| 2019 |
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). The Lancet. Haematology. PMID 30935953 DOI: 10.1016/S2352-3026(19)30026-2 |
0.369 |
|
| 2019 |
Caglayan C, Dixon J, Wall A, Salles GA, Hoster E, Hiddemann W, Herold M, Morschhauser F, Sebban C, Hagenbeek A, Marcus R, Hochster H, Rummel MJ, Kimby E, Vitolo U, et al. A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group Blood. 134: 2812-2812. DOI: 10.1182/Blood-2019-122328 |
0.31 |
|
| 2018 |
Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, Van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, Van Tinteren H, Kersten MJ. Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study. Haematologica. PMID 30381303 DOI: 10.3324/Haematol.2018.196899 |
0.363 |
|
| 2018 |
Hagenbeek A, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu RD, Burggraaf CN, Nijland M, Tonino SH, Tinteren Hv, Yurda MIL, Kersten MJ. Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study Blood. 132: 2923-2923. DOI: 10.1182/Blood-2018-99-112235 |
0.411 |
|
| 2017 |
Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Phreundschuh M, Jack A, ... ... Hagenbeek A, et al. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica. PMID 28411252 DOI: 10.3324/Haematol.2017.165415 |
0.356 |
|
| 2017 |
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28379322 DOI: 10.1093/Annonc/Mdx097 |
0.356 |
|
| 2016 |
van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, ... ... Hagenbeek A, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016690198. PMID 28029326 DOI: 10.1200/Jco.2016.69.0198 |
0.388 |
|
| 2016 |
Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, et al. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016708651. PMID 28029309 DOI: 10.1200/Jco.2016.70.8651 |
0.364 |
|
| 2016 |
Flowers C, Ou F, Shi Q, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus RE, Kimby E, Herold M, De Bedout S, Nielsen T, Morschhauser F, ... ... Hagenbeek A, et al. Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study Blood. 128: 1102-1102. DOI: 10.1182/Blood.V128.22.1102.1102 |
0.318 |
|
| 2015 |
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. The Lancet. Oncology. 16: 704-15. PMID 25925619 DOI: 10.1016/S1470-2045(15)70128-2 |
0.355 |
|
| 2015 |
Sargent DJ, Shi Q, Bedout SD, Flowers C, Fowler NH, Fu T, Hagenbeek A, Herold M, Hoster E, Huang J, Kimby E, Ladetto M, Morschhauser F, Nielsen T, Takeshita K, et al. Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts). Journal of Clinical Oncology. 33: 8504-8504. DOI: 10.1200/Jco.2015.33.15_Suppl.8504 |
0.35 |
|
| 2014 |
Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. Journal of Clinical Pharmacology. 54: 818-27. PMID 24443277 DOI: 10.1002/Jcph.268 |
0.39 |
|
| 2014 |
Morschhauser F, Flinn I, Advani RH, Sehn LH, Kolibaba KS, Press OW, Salles GA, Diefenbach CSM, Tilly H, Assouline SE, Chen AT, Dreyling MH, Hagenbeek A, Zinzani PL, Cheson BD, et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology. 32: 8519-8519. DOI: 10.1200/Jco.2014.32.15_Suppl.8519 |
0.359 |
|
| 2014 |
Imhoff GWv, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Fennessy M, Liao Q, Holt Bvd, ... ... Hagenbeek A, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928) Blood. 124: 630-630. DOI: 10.1182/Blood.V124.21.630.630 |
0.41 |
|
| 2014 |
Morschhauser F, Flinn I, Advani RH, Diefenbach CS, Kolibaba K, Press OW, Sehn LH, Chen AI, Salles G, Tilly H, Cheson BD, Assouline S, Dreyling M, Hagenbeek A, Zinzani PL, et al. Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Blood. 124: 4457-4457. DOI: 10.1182/Blood.V124.21.4457.4457 |
0.311 |
|
| 2013 |
Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1977-83. PMID 23547079 DOI: 10.1200/Jco.2012.45.6400 |
0.33 |
|
| 2013 |
Salles GA, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Bouabdallah R, Catalano J, Pauline B, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, ... ... Hagenbeek A, et al. Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy Blood. 122: 509-509. DOI: 10.1182/Blood.V122.21.509.509 |
0.401 |
|
| 2013 |
Kater AP, Tonino SH, Kersten MJ, Hagenbeek A, Spiering M, Oers MHv, Xin Y, Ramanathan S, Aiello M, Jun S. Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies Blood. 122: 2881-2881. DOI: 10.1182/Blood.V122.21.2881.2881 |
0.372 |
|
| 2012 |
Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, ... ... Hagenbeek A, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 119: 3698-704. PMID 22389254 DOI: 10.1182/Blood-2011-09-378323 |
0.427 |
|
| 2011 |
van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin's lymphoma. Best Practice & Research. Clinical Haematology. 24: 231-56. PMID 21658621 DOI: 10.1016/J.Beha.2011.03.002 |
0.376 |
|
| 2011 |
Hagenbeek A. Preface on follicular non-Hodgkin's lymphoma. Best Practice & Research. Clinical Haematology. 24: 93. PMID 21658610 DOI: 10.1016/J.Beha.2011.03.009 |
0.301 |
|
| 2011 |
Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, ... ... Hagenbeek A, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 117: 7070-8. PMID 21536860 DOI: 10.1182/Blood-2011-04-345256 |
0.391 |
|
| 2011 |
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, ... ... Hagenbeek A, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 377: 42-51. PMID 21176949 DOI: 10.1016/S0140-6736(10)62175-7 |
0.368 |
|
| 2011 |
Hagenbeek A. VIII. Radioimmunotherapy in malignant lymphoma: an underused tool? Annals of Oncology. 22: 51-53. DOI: 10.1093/Annonc/Mdr174 |
0.402 |
|
| 2010 |
van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJ, Parren PW, van de Winkel JG, Ebeling SB, Martens AC. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. Haematologica. 95: 2063-71. PMID 20851867 DOI: 10.3324/Haematol.2010.025783 |
0.309 |
|
| 2010 |
Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leukemia & Lymphoma. 51: 20-7. PMID 20815760 DOI: 10.3109/10428194.2010.500047 |
0.419 |
|
| 2010 |
van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2853-8. PMID 20439641 DOI: 10.1182/Blood.V112.11.836.836 |
0.36 |
|
| 2010 |
van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2246-52. PMID 20368567 DOI: 10.1200/Jco.2009.25.0852 |
0.408 |
|
| 2010 |
van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Seminars in Hematology. 47: 199-210. PMID 20350667 DOI: 10.1053/J.Seminhematol.2010.01.007 |
0.318 |
|
| 2010 |
Oers MHJv, Tönnissen E, Glabbeke MV, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, Reijden BAvd. Reply to U. Dührsen et al Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.30.8353 |
0.369 |
|
| 2010 |
Hagenbeek A, Radford J, Hoof AV, Vitolo U, Rohatiner AZS, Salles G, Soubeyran P, Tilly H, Delaloye AB, Putten WLJv, Morschhauser F. 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients Blood. 116: 594-594. DOI: 10.1182/Blood.V116.21.594.594 |
0.394 |
|
| 2010 |
Salles GA, Catalano J, Feugier P, Offner FC, Bouabdallah R, Caballero D, Brice P, Pedersen LM, Haioun C, Belada D, Delmer A, Simpson D, Tilly H, Leppa S, Soubeyran P, ... Hagenbeek A, et al. Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy. Blood. 116: 1788-1788. DOI: 10.1182/Blood.V116.21.1788.1788 |
0.412 |
|
| 2009 |
Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6094-100. PMID 19858392 DOI: 10.1200/Jco.2009.22.6258 |
0.37 |
|
| 2009 |
Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 1837-43. PMID 19837764 DOI: 10.2967/Jnumed.109.067587 |
0.387 |
|
| 2009 |
Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. The Lancet. Oncology. 10: 1160-70. PMID 19828373 DOI: 10.1016/S1470-2045(09)70258-X |
0.315 |
|
| 2009 |
Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G. Biomarkers and prognosis in malignant lymphomas. Clinical Lymphoma & Myeloma. 9: 160-6. PMID 19406728 DOI: 10.3816/Clm.2009.N.038 |
0.365 |
|
| 2009 |
Hagenbeek A. Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1540-2. PMID 19255319 DOI: 10.1200/Jco.2008.19.8457 |
0.408 |
|
| 2009 |
de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, de Boer JP, van Glabbeke M. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 94: 70-7. PMID 19059937 DOI: 10.3324/Haematol.13574 |
0.319 |
|
| 2009 |
van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. British Journal of Haematology. 144: 524-30. PMID 19036081 DOI: 10.1111/J.1365-2141.2008.07498.X |
0.389 |
|
| 2009 |
Jong Dd, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Hagenbeek A, Horning S, Lister A, Raemaekers J, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma Journal of Clinical Pathology. 62: 128-138. PMID 18794197 DOI: 10.1136/Jcp.2008.057257 |
0.33 |
|
| 2009 |
Hagenbeek A, Fayad L, Delwail V, Rossi JF, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, et al. Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Blood. 114: 935-935. DOI: 10.1182/Blood.V114.22.935.935 |
0.445 |
|
| 2008 |
Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, ... ... Hagenbeek A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5156-64. PMID 18854568 DOI: 10.1200/Jco.2008.17.2015 |
0.397 |
|
| 2008 |
Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica. 93: 1702-11. PMID 18728020 DOI: 10.3324/Haematol.13311 |
0.308 |
|
| 2008 |
Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 111: 5486-95. PMID 18390837 DOI: 10.1182/Blood-2007-10-117671 |
0.435 |
|
| 2007 |
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, ... ... Hagenbeek A, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. The New England Journal of Medicine. 357: 1916-27. PMID 17989384 DOI: 10.1056/Nejmoa064601 |
0.344 |
|
| 2007 |
de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 805-12. PMID 17327602 DOI: 10.1200/Jco.2006.09.4490 |
0.348 |
|
| 2007 |
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 579-86. PMID 17242396 DOI: 10.1200/Jco.2006.09.2403 |
0.305 |
|
| 2007 |
Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. European Journal of Haematology. Supplementum. 5-14. PMID 17206982 DOI: 10.1111/J.1600-0609.2006.00789.X |
0.42 |
|
| 2007 |
Reijden BAvd, Oers MHJV, Tonissen E, Glabbeke MV, Giurgia L, Klasa R, Marcus RE, Wolf M, Veer MVt, Vranovsky A, Holte H, Kimby E, Hagenbeek A. BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial. Blood. 110: 791-791. DOI: 10.1182/Blood.V110.11.791.791 |
0.392 |
|
| 2007 |
Hagenbeek A, Bischof-Delaloye A, Radford JA, Rohatiner A, Salles G, Hoof AV, Putz B, Kunz M, Morschhauser F. 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients. Blood. 110: 643-643. DOI: 10.1182/Blood.V110.11.643.643 |
0.404 |
|
| 2007 |
Bischof-Delaloye A, Antonescu C, Hagenbeek A. Dosimetric Analysis of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Given as Consolidation of First Remission in Patients with Advanced-Stage Follicular Lymphoma in the International Phase 3 First-Line Indolent Trial (FIT). Blood. 110: 3415-3415. DOI: 10.1182/Blood.V110.11.3415.3415 |
0.326 |
|
| 2007 |
Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Hagenbeek A, Lister A, Rohatiner A. Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A ’Real-Time’ MBR RQ-PCR Analysis. Blood. 110: 3412-3412. DOI: 10.1182/Blood.V110.11.3412.3412 |
0.334 |
|
| 2007 |
Gondek K, Shah S, Bischof-Delaloye A, Rohatiner A, Salles G, Putz B, Kunz M, Hagenbeek A. Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT). Blood. 110: 3319-3319. DOI: 10.1182/Blood.V110.11.3319.3319 |
0.306 |
|
| 2006 |
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 108: 3295-301. PMID 16873669 DOI: 10.1182/Blood-2006-05-021113 |
0.34 |
|
| 2006 |
van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4027-35. PMID 16818702 DOI: 10.1158/1078-0432.Ccr-06-0066 |
0.326 |
|
| 2006 |
Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3128-35. PMID 16754934 DOI: 10.1200/Jco.2005.05.2746 |
0.356 |
|
| 2006 |
Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1590-6. PMID 16575010 DOI: 10.1200/Jco.2005.03.7952 |
0.373 |
|
| 2006 |
Ivanov R, Hagenbeek A, Ebeling S. Towards immunogene therapy of hematological malignancies. Experimental Hematology. 34: 251-63. PMID 16543059 DOI: 10.1016/J.Exphem.2005.10.004 |
0.415 |
|
| 2006 |
Cheson BD, Pfistner B, Juweid ME, Horning SJ, Coiffier B, Gascoyne RD, Fisher RI, Hagenbeek A, Hoppe RT, Diehl V. Recommendations for revised response criteria for malignant lymphoma Journal of Clinical Oncology. 24: 7507-7507. DOI: 10.1200/Jco.2006.24.18_Suppl.7507 |
0.304 |
|
| 2006 |
Veer MBV, Notenboom A, McKenzie M, Kluin-Nelemans H, Oers Rv, Zijlstra J, Jong Dd, Sonneveld P, Hagenbeek A. First report of the HOVON 45 : A phase II study with rituximab, high dose Ara-C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma. Blood. 108: 2734-2734. DOI: 10.1182/Blood.V108.11.2734.2734 |
0.365 |
|
| 2006 |
Meerten Tv, Rozemuller H, Mackus WJM, Parren PWHI, Winkel JGJvd, Claessen M, Rijn RSv, Hagenbeek A, Martens ACM, Ebeling SB. 428. Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer Molecular Therapy. 13: 5488-5488. DOI: 10.1016/J.Ymthe.2006.08.493 |
0.309 |
|
| 2005 |
Ivanov R, Hol S, Aarts T, Hagenbeek A, Slager EH, Ebeling S. UTY-specific TCR-transfer generates potential graft-versus-leukaemia effector T cells. British Journal of Haematology. 129: 392-402. PMID 15842664 DOI: 10.1111/J.1365-2141.2005.05461.X |
0.326 |
|
| 2005 |
Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma Annals of Oncology. 16: 786-792. PMID 15802280 DOI: 10.1093/Annonc/Mdi148 |
0.405 |
|
| 2005 |
Hagenbeek A. Future trends in radioimmunotherapy. Seminars in Oncology. 32: S57-62. PMID 15786027 DOI: 10.1053/J.Seminoncol.2005.01.015 |
0.402 |
|
| 2005 |
Ivanov R, Aarts T, Hol S, Doornenbal A, Hagenbeek A, Petersen E, Ebeling S. Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1694-703. PMID 15755990 DOI: 10.1158/1078-0432.Ccr-04-1772 |
0.316 |
|
| 2005 |
Ferme C, Diviné M, Vranovsky A, Morschhauser F, Bouabdallah R, Gabarre J, Bastard-Stamatoullas A, Delarue R, Zagonel V, Jaubert J, Hagenbeek A, Kramer MHH, Rieux C, Thomas J, Henry-Amar M. Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial. Blood. 106: 813-813. DOI: 10.1182/Blood.V106.11.813.813 |
0.405 |
|
| 2005 |
Meerten Tv, Rijn RSv, Hagenbeek A, Ebeling SB. Complement-Induced Cell Death by Rituximab Depends on CD20-Expression Level and Acts Complementary to Antibody-Dependent Cell-Mediated Cytotoxicity. Blood. 106: 775-775. DOI: 10.1182/Blood.V106.11.775.775 |
0.312 |
|
| 2005 |
Meerten Tv, Mackus WJM, Parren PWHI, Winkel JGJvd, Hagenbeek A, Ebeling SB. A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation. Blood. 106: 5538-5538. DOI: 10.1182/Blood.V106.11.5538.5538 |
0.336 |
|
| 2005 |
Morschhauser F, Radford J, Hoof Av, Kuss [V, Chlistalla A, Hagenbeek A, Hugh-Jones C. Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy Blood. 106: 4795-4795. DOI: 10.1182/Blood.V106.11.4795.4795 |
0.36 |
|
| 2005 |
Hagenbeek A, Plesner T, Johnson P, Pedersen L, Walewski J, Hellmann A, Link B, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Petersen J, Radford J. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody : Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. Blood. 106: 4760-4760. DOI: 10.1182/Blood.V106.11.4760.4760 |
0.413 |
|
| 2005 |
Dijk MCC, Rijn RSv, Simonetti ER, Hogenes MC, Smulders S, Weger RAd, Hagenbeek A, Tweel JGvd, Verdonck LF, Martens ACM, Ebeling SB. Induction of Xenogeneic Graft-Versus-Host Disease through Administration of HuPBMC to Immune Deficient RAG2−/−γc−/− Mice: A Model for B Cell-Involvement in Chronic Graft-Versus-Host Disease. Blood. 106: 3099-3099. DOI: 10.1182/Blood.V106.11.3099.3099 |
0.313 |
|
| 2005 |
Ivanov R, Aarts T, Hagenbeek A, Hol S, Ebeling S. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC Cytotherapy. 7: 62-73. DOI: 10.1016/S1465-3249(05)70790-8 |
0.347 |
|
| 2004 |
Rozemuller H, Knaän-Shanzer S, Hagenbeek A, van Bloois L, Storm G, Martens AC. Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes. Experimental Hematology. 32: 1118-25. PMID 15539091 DOI: 10.1016/J.Exphem.2004.08.002 |
0.302 |
|
| 2004 |
Weijtens M, van Spronsen A, Hagenbeek A, de Weger R, Martens A. Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat. Experimental Hematology. 32: 962-9. PMID 15504552 DOI: 10.1016/J.Exphem.2004.07.009 |
0.355 |
|
| 2004 |
Otten HG, van Ginkel WG, Hagenbeek A, Petersen EJ. Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia. Leukemia. 18: 1401-5. PMID 15215873 DOI: 10.1038/Sj.Leu.2403414 |
0.394 |
|
| 2004 |
Kersten MJ, Jong Dd Dd, Raemaekers JM, Kluin PM, Hagenbeek A. Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphoma A meeting report of the Second International Lunenburg Lymphoma Workshop. The Hematology Journal : the Official Journal of the European Haematology Association. 5: 202-8. PMID 15167905 DOI: 10.1038/Sj.Thj.6200376 |
0.36 |
|
| 2004 |
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, ... ... Hagenbeek A, et al. Follicular lymphoma international prognostic index. Blood. 104: 1258-65. PMID 15126323 DOI: 10.1182/Blood-2003-12-4434 |
0.363 |
|
| 2004 |
Oers MHJV, Glabbeke MV, Teodorovic I, Rozewicz C, Klasa R, Marcus RE, Wolf M, Kimby E, Hagenbeek A. Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial. Blood. 104: 586-586. DOI: 10.1182/Blood.V104.11.586.586 |
0.391 |
|
| 2004 |
Rijn RSv, Simonetti ER, Storm G, Bonyhadi M, Hagenbeek A, Martens ACM, Ebeling SB. Quantitative Assessment of the Impact of Ex Vivo Manipulation on the In Vivo Functionality of Human T Cells in RAG2−/− γc−/− mice. Blood. 104: 450-450. DOI: 10.1182/Blood.V104.11.450.450 |
0.334 |
|
| 2004 |
Ivanov R, Hol S, Aarts T, Hagenbeek A, Ebeling S. Generation of Graft-Versus-Leukemia (GVL)-Effector T Cells through Targeting of Leukemia-Associated HY Antigens Via TCR Transfer. Blood. 104: 2117-2117. DOI: 10.1182/Blood.V104.11.2117.2117 |
0.324 |
|
| 2004 |
Hagenbeek A, Plesner T, Walewski J, Hellmann A, Link BK, Dalby LW. HuMax-CD20 Fully Human Monoclonal Antibody in Follicular Lymphoma. First Human Exposure: Early Results of an Ongoing Phase I/II Trial. Blood. 104: 1400-1400. DOI: 10.1182/Blood.V104.11.1400.1400 |
0.405 |
|
| 2003 |
Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leukemia & Lymphoma. 44: S37-47. PMID 15154741 DOI: 10.1080/10428190310001616944 |
0.42 |
|
| 2003 |
Hagenbeek A, Delaloye AB. Editorial perspective--advances in B-cell non-Hodgkin's lymphoma. Leukemia & Lymphoma. 44. PMID 15154737 DOI: 10.1080/10428190310001616908 |
0.387 |
|
| 2003 |
van Agthoven M, Sonneveld P, Hagenbeek A, Uyl-de Groot CA. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. The Hematology Journal : the Official Journal of the European Haematology Association. 4: 399-409. PMID 14671611 DOI: 10.1038/Sj.Thj.6200323 |
0.349 |
|
| 2003 |
Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, ... ... Hagenbeek A, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. The New England Journal of Medicine. 348: 2396-406. PMID 12802025 DOI: 10.1056/Nejmoa022628 |
0.386 |
|
| 2003 |
van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood. 102: 2522-31. PMID 12791667 DOI: 10.1182/Blood-2002-10-3241 |
0.306 |
|
| 2003 |
Ebeling SB, Ivanov R, Hol S, Aarts TI, Hagenbeek A, Verdonck LF, Petersen EJ. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells. British Journal of Haematology. 121: 721-9. PMID 12780786 DOI: 10.1046/J.1365-2141.2003.04341.X |
0.341 |
|
| 2003 |
Ebeling SB, Eric Borst HP, Simonetti ER, Hol S, Garin MI, Slaper-Cortenbach I, Hagenbeek A. Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene. Journal of Virological Methods. 109: 177-86. PMID 12711061 DOI: 10.1016/S0166-0934(03)00069-7 |
0.316 |
|
| 2003 |
Kolen S, Weijtens M, Hagenbeek A, van Spronsen A, Smulders S, de Weger R, de Witte T, Dolstra H, van de Wiel van Kemenade E, Martens A. Monitoring of developing graft-versus-host disease mediated by herpes simplex virus thymidine kinase gene-transduced T cells. Human Gene Therapy. 14: 341-51. PMID 12659675 DOI: 10.1089/104303403321208943 |
0.348 |
|
| 2002 |
Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Rituximab therapy for indolent non-Hodgkin's lymphoma Anti-Cancer Drugs. 13. PMID 12710586 DOI: 10.1097/00001813-200211002-00003 |
0.428 |
|
| 2002 |
Oers MHJV, Hagenbeek A, Glabbeke MV, Teodorovic I. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study. Annals of Hematology. 81: 553-557. PMID 12424535 DOI: 10.1007/S00277-002-0548-2 |
0.345 |
|
| 2002 |
van Agthoven M, Groot MT, Verdonck LF, Löwenberg B, Schattenberg AV, Oudshoorn M, Hagenbeek A, Cornelissen JJ, Uyl-de Groot CA, Willemze R. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplantation. 30: 243-51. PMID 12203141 DOI: 10.1038/Sj.Bmt.1703641 |
0.315 |
|
| 2002 |
Weijtens M, van Spronsen A, Hagenbeek A, Braakman E, Martens A. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. Human Gene Therapy. 13: 187-98. PMID 11812276 DOI: 10.1089/10430340252769725 |
0.352 |
|
| 2002 |
Groot M, Agthoven Mv, Verdonck L, Löwenberg B, Schattenberg A, Oudshoorn M, Hagenbeek A, Cornelissen J, Groot CU, Willemze R. Pcn1 Cost Analysis Of Hla-Identical Sibling And Voluntary Unrelated Allogeneic Bone Marrow And Peripheral Blood Stem Cell Transplantation In Adults With Acute Myelocytic Leukaemia Or Acute Lymphoblastic Leukaemia Value in Health. 5: 536. DOI: 10.1016/S1098-3015(10)61418-0 |
0.333 |
|
| 2001 |
Chalmers D, Ferrand C, Apperley JF, Melo JV, Ebeling S, Newton I, Duperrier A, Hagenbeek A, Garrett E, Tiberghien P, Garin M. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 146-8. PMID 11482986 DOI: 10.1006/Mthe.2001.0433 |
0.315 |
|
| 2001 |
Weerdt Od, Donk NWCJvd, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Netherlands Journal of Medicine. 59: 50-56. PMID 11476912 DOI: 10.1016/S0300-2977(01)00140-1 |
0.402 |
|
| 1999 |
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas Journal of Clinical Oncology. 17: 1244-1244. PMID 10561185 DOI: 10.1200/Jco.1999.17.4.1244 |
0.336 |
|
| 1999 |
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 423-9. PMID 10458261 DOI: 10.1200/Jco.1999.17.1.423 |
0.377 |
|
| 1999 |
Braakman E, Vogels R, Martens AC, Vermeulen J, Bron M, Hoogerbrugge PM, Valerio D, Hagenbeek A. Ganciclovir-mediated in vivo elimination of myeloid leukemic cells expressing the HSVtk gene induces HSVtk loss variants. Gene Therapy. 6: 1139-46. PMID 10455417 DOI: 10.1038/Sj.Gt.3300913 |
0.321 |
|
| 1999 |
Vellenga E, Putten vWLJ, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeek A, Jonkhoff AR, Huijgens PC, Verdonck LF, Lelie vdJ, Schouten HC, Gmur J, Wijermans P, Gratwohl A, Hess U, et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia Bone Marrow Transplantation. 23: 1279-1282. PMID 10414916 DOI: 10.1038/Sj.Bmt.1701799 |
0.404 |
|
| 1999 |
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 10: 13-9. PMID 10076716 DOI: 10.1023/A:1008397220178 |
0.367 |
|
| 1998 |
Rozemuller H, Terpstra W, Rombouts EJC, Lawler M, Byrne C, FitzGerald DJP, Kreitman RJ, Wielenga JJ, Löwenberg B, Touw IP, Hagenbeek A, Martens ACM. GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF Leukemia. 12: 1962-1970. PMID 9844926 DOI: 10.1038/Sj.Leu.2401205 |
0.346 |
|
| 1998 |
Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn J, Somers R, Sonneveld P, Gisselbrecht C, Lelie HVd, Chauvin F. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. Journal of Clinical Oncology. 16: 3264-3269. PMID 9779700 DOI: 10.1200/Jco.1998.16.10.3264 |
0.4 |
|
| 1998 |
Gowing H, Braakman E, Hagenbeek A, Lawler M, Mccann SR, Pamphilon DH, Martens ACM. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation Bone Marrow Transplantation. 21: 801-807. PMID 9603404 DOI: 10.1038/Sj.Bmt.1701164 |
0.314 |
|
| 1998 |
Rozemuller H, Rombouts EJC, Touw IP, FitzGerald DJP, Kreitman RJ, Hagenbeek A, Martens A. In vivo targeting of leukemic cells using diphtheria toxin fused to murine CM-CSF Leukemia. 12: 710-717. PMID 9593269 DOI: 10.1038/Sj.Leu.2400990 |
0.348 |
|
| 1998 |
Bos GMJ, Putten WLJv, Holt Bvd, Bent Mvd, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Annals of Oncology. 9: 191-194. PMID 9553665 DOI: 10.1023/A:1008260120532 |
0.317 |
|
| 1998 |
Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 41-7. PMID 9440721 DOI: 10.1200/Jco.1998.16.1.41 |
0.399 |
|
| 1998 |
Blay JY, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T. The International Prognostic Index Correlates to Survival in Patients With Aggressive Lymphoma in Relapse: Analysis of the PARMA Trial Blood. 92: 3562-3568. DOI: 10.1182/Blood.V92.10.3562 |
0.388 |
|
| 1997 |
Terpstra W, Rozemuller H, Breems DA, Rombouts EJC, Prins A, FitzGerald DJP, Kreitman RJ, Wielenga JJ, Ploemacher RE, Löwenberg B, Hagenbeek A, Martens ACM. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells. Blood. 90: 3735-3742. DOI: 10.1182/Blood.V90.9.3735 |
0.341 |
|
| 1997 |
Meerwaldt JH, Carde P, Somers R, Thomas J, Kluin-Nelemans J, Bron D, Noordijk EM, Cosset JM, Bijnens L, Teodorovic I, Hagenbeek A. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma Annals of Oncology. 8: 67-70. DOI: 10.1093/Annonc/8.Suppl_1.S67 |
0.398 |
|
| 1997 |
Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, Hoof Av, Thomas J, Noordijk E. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial Annals of Oncology. 8: 111-114. DOI: 10.1093/Annonc/8.Suppl_1.S111 |
0.393 |
|
| 1997 |
Noordijk E, Carde P, Hagenbeek A, Mandard A, Kluin-Nelemans J, Thomas J, Tirelli U, Monconduit M, Eghbali H, Burgers J, Dupouy N, Henry-Amar M. 77 Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease six-year results of the EORTC-GPMC controlled clinical trials ‘H7-VF’, ‘H7-F’ and ‘H7-U’ International Journal of Radiation Oncology Biology Physics. 39: 173. DOI: 10.1016/S0360-3016(97)80635-9 |
0.328 |
|
| 1996 |
Arkesteijn GJA, Erpelinck SLA, Martens ACM, Hagemeijer A, Hagenbeek A. The use of FISH with chromosome-specific repetitive DNA probes for the follow-up of leukemia patients. Correlations and discrepancies with bone marrow cytology. Cancer Genetics and Cytogenetics. 88: 69-75. PMID 8630983 DOI: 10.1016/0165-4608(95)00278-2 |
0.341 |
|
| 1995 |
Verdonck LF, Putten WLJv, Hagenbeek A, Schouten HC, Sonneveld P, Imhoff GWv, Kluin-Nelemans HC, Raemaekers JMM, Oers RHJv, Haak HL, Schots R, Dekker AW, Gast GCd, Löwenberg B. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma The New England Journal of Medicine. 332: 1045-1051. PMID 7898521 DOI: 10.1056/Nejm199504203321601 |
0.431 |
|
| 1995 |
Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, Façon T, Gratwohl A, Hagenbeek A, Jacobs P. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma Journal of Clinical Oncology. 13: 1312-1322. PMID 7751876 DOI: 10.1200/Jco.1995.13.6.1312 |
0.379 |
|
| 1995 |
Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Leeuwen FEV, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, Gospodarowicz MK, Wacholder S, Inskip PD, Tucker MA, Boice JD. Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's Lymphoma Journal of the National Cancer Institute. 87: 524-531. PMID 7707439 DOI: 10.1093/Jnci/87.7.524 |
0.313 |
|
| 1995 |
Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, Glabbeke Mv, Somers R, Bijnens L, Noordijk EM, Peeters CD. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology. 13: 2819-2826. PMID 7595744 DOI: 10.1200/Jco.1995.13.11.2819 |
0.408 |
|
| 1994 |
van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 1063-73. PMID 8164031 DOI: 10.1200/Jco.1994.12.5.1063 |
0.397 |
|
| 1994 |
Leeuwen FEV, Klokman WJ, Hagenbeek A, Noyon R, Belt-Dusebout AWVD, Kerkhoff EHMV, Heerde PV, Somers R. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. Journal of Clinical Oncology. 12: 312-325. PMID 8113838 DOI: 10.1200/Jco.1994.12.2.312 |
0.307 |
|
| 1994 |
Travis LB, Curtis RE, Stovall M, Holowaty EJ, Leeuwen FEV, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, Gospodarowicz MK, Adami J, Wacholder S, Inskip PD, Tucker MA, et al. Risk of Leukemia Following Treatment for Non-Hodgkin's Lymphoma Journal of the National Cancer Institute. 86: 1450-1457. PMID 8089863 DOI: 10.1093/Jnci/86.19.1450 |
0.379 |
|
| 1994 |
Groot CJD, Martens ACM, Hagenbeek A. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo European Journal of Cancer. 30: 2137-2143. PMID 7857714 DOI: 10.1016/0959-8049(94)00441-7 |
0.334 |
|
| 1994 |
Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, De Pauw BE, Breed WPM, Verdonck L, Burgers JMV, Eghbali H, Zittoun R. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A european organization for research and treatment of cancer lymphoma cooperative group and Groupe Pierre-et-Marie-Curie controlled clinical trial Journal of Clinical Oncology. 12: 279-287. PMID 7509381 DOI: 10.1200/Jco.1994.12.2.279 |
0.369 |
|
| 1993 |
Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJ, Noordijk EM, Tanguy A, Meerwaldt JH, Fur RL. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology. 11: 2258-2272. PMID 7693881 DOI: 10.1200/Jco.1993.11.11.2258 |
0.332 |
|
| 1993 |
Aelst Fv, Löwenberg B, Sizoo W, Anker PJvd, Veer Mv, Hagenbeek A. Allogeneic bone marrow transplantation for chronic myelogenous leukemia European Journal of Cancer. 29. DOI: 10.1016/0959-8049(93)91447-S |
0.313 |
|
| 1992 |
Thomas J, Pauw Bd, Hagenbeek A, Somers R, Carde P, Tirelli U, Duez N. Phase II study of cytarabine in Hodgkin's disease European Journal of Cancer. 28: 857-859. PMID 1524908 DOI: 10.1016/0959-8049(92)90133-M |
0.373 |
|
| 1991 |
Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, Gisselbrecht C, Nelemans JCK, Somers R, Misset JC. PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients) Annals of Oncology. 2: 57-64. PMID 2043500 DOI: 10.1093/Annonc/2.Suppl_1.57 |
0.418 |
|
| 1991 |
Carde P, Meerwaldt JH, Glabbeke Mv, Somers R, Monconduit M, Thomas J, Wolf-Peeters Cd, Pauw Bd, Tanguy A, Kluin-Nelemans JC, Noordijk EM, Regnier R, Bron D, Lustinan-Marechal J, Caillou B, ... ... Hagenbeek A, et al. Original article: Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade Non-Hodgkin's Lymphoma (NHL): The 1980–1985 EORTC trial|* Annals of Oncology. 2: 431-435. PMID 1722697 DOI: 10.1093/Oxfordjournals.Annonc.A057979 |
0.372 |
|
| 1991 |
Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger D, Fernandez-Ranada J. Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation Blood. 77: 1587-1592. DOI: 10.1182/Blood.V77.7.1587.Bloodjournal7771587 |
0.428 |
|
| 1990 |
Martens ACM, Bekkum DWv, Hagenbeek A. Minimal residual disease in leukemia: studies in an animal model for acute myelocytic leukemia (BNML). Stem Cells. 8: 27-38. PMID 2403582 DOI: 10.1002/Stem.5530080105 |
0.38 |
|
| 1990 |
Arkesteijn GJA, Dekken Hv, Martens ACM, Hagenbeek A. Clinical applications of flow karyotyping in myelocytic leukemia by stimulation of different subpopulations of cells in blood or bone marrow samples. Cytometry. 11: 196-201. PMID 2307058 DOI: 10.1002/Cyto.990110122 |
0.33 |
|
| 1990 |
Bekkum DWv, Hagenbeek A. Immunohematological aspects of total body irradiation and bone marrow transplantation for the treatment of leukemia. Radiotherapy and Oncology. 18: 30-36. PMID 2247647 DOI: 10.1016/0167-8140(90)90176-W |
0.402 |
|
| 1990 |
Löwenberg B, Putten WLJv, Verdonck LF, Dekker AW, Gast GCd, Willemze R, Zwaan FE, Abels J, Sonneveld P, Lelie Jvd, Goudsmit R, Sizoo W, Hagenbeek A. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study. Haematology and Blood Transfusion. 33: 655-659. PMID 2182456 DOI: 10.1007/978-3-642-74643-7_119 |
0.392 |
|
| 1990 |
Nooter K, Vries Ad, Martens ACM, Hagenbeek A. Effect of cyclophosphamide pretreatment on daunorubicin in rat acute leukaemia model. European Journal of Cancer and Clinical Oncology. 26: 729-732. PMID 2144163 DOI: 10.1016/0277-5379(90)90129-H |
0.348 |
|
| 1990 |
Ruit JB, Löwenberg B, Hagenbeek A, Verhoef GEG, Wielenga JJ, Michiels J, Sizoo W. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma. Seminars in Oncology. 17: 24-27. DOI: 10.5555/Uri:Pii:009377549090120R |
0.4 |
|
| 1989 |
Jansen RF, van Geel BN, van der Zee J, Hagenbeek A, Levendag PC. Intractible cutaneous non-Hodgkin's lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with 1-phenylalanine-mustard (melphalan, L-Pam). Cancer. 64: 392-5. PMID 2736485 DOI: 10.1002/1097-0142(19890715)64:2<392::Aid-Cncr2820640209>3.0.Co;2-L |
0.313 |
|
| 1988 |
Van der Velden JW, Van Putten WLJ, Guinee VF, Pfeiffer R, Van Leeuwen FE, Van der Linden EAM, Vardomskaya I, Lane W, Durand M, Lagarde C, Hagemeister FB, Hagenbeek A, Eghbali H. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease International Journal of Cancer. 42: 252-255. PMID 3403068 DOI: 10.1002/Ijc.2910420218 |
0.372 |
|
| 1988 |
Kokenberg E, Sonneveld P, Sizoo W, Hagenbeek A, Löwenberg B. Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. Journal of Clinical Oncology. 6: 802-812. PMID 3163363 DOI: 10.1200/Jco.1988.6.5.802 |
0.349 |
|
| 1987 |
Vellenga E, Sizoo W, Hagenbeek A, Löwenberg B. Different repopulation kinetics of erythroid (BFU-E), myeloid (CFU-GM) and T lymphocyte (TL-CFU) progenitor cells after autologous and allogeneic bone marrow transplantation. British Journal of Haematology. 65: 137-142. PMID 3548797 DOI: 10.1111/J.1365-2141.1987.Tb02255.X |
0.37 |
|
| 1987 |
Martens ACM, Hagenbeek A. Kinetics of normal hemopoietic stem cells during leukemia growth before and after induction of a complete remission. Studies in a rat model for acute myelocytic leukemia (BNML). Leukemia Research. 11: 453-459. PMID 3472017 DOI: 10.1016/0145-2126(87)90077-4 |
0.381 |
|
| 1987 |
Varekamp AE, Vries AJd, Zurcher C, Hagenbeek A. Lung damage following bone marrow transplantation: II. The contribution of cyclophosphamide. International Journal of Radiation Oncology Biology Physics. 13: 1515-1521. PMID 3305444 DOI: 10.1016/0360-3016(87)90319-1 |
0.318 |
|
| 1987 |
Löwenberg B, Abels J, Bekkum DWv, Sizoo W, Hendriks WDH, Veer MBv, Wagemaker G, Sintnicolaas K, Hagenbeek A. Treatment of patients with acute myeloid leukemia in first remission with marrow ablative therapy and autologous bone marrow transplantation. Haematology and Blood Transfusion. 30: 233-236. PMID 3305201 DOI: 10.1007/978-3-642-71213-5_34 |
0.403 |
|
| 1987 |
Zurcher C, Varekamp AE, Solleveld HA, Durham SK, Vries AJD, Hagenbeek A. Late Effects of Cyclophosphamide and Total Body Irradiation as a Conditioning Regimen for Bone Marrow Transplantation in Rats (a Preliminary Report) International Journal of Radiation Biology. 51: 1059-1068. PMID 3298105 DOI: 10.1080/09553008714551351 |
0.371 |
|
| 1987 |
Hagenbeek A, Brummelhuis HGJ, Donkers A, Dumas AM, Haaft At, Schaap BJP, Sizoo W, Löwenberg B. Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. The Journal of Infectious Diseases. 155: 897-902. PMID 3031172 DOI: 10.1093/Infdis/155.5.897 |
0.356 |
|
| 1987 |
Martens ACM, Schultz FW, Hagenbeek A. Nonhomogeneous Distribution of Leukemia in the Bone Marrow During Minimal Residual Disease Blood. 70: 1073-1078. DOI: 10.1182/Blood.V70.4.1073.1073 |
0.338 |
|
| 1987 |
Varekamp AE, Zurcher C, Hagenbeek A. Interstitial pneumonitis following bone marrow transplantation: the reciprocal interference of radiation and graft versus host disease International Journal of Radiation Oncology Biology Physics. 13: 155. DOI: 10.1016/0360-3016(87)91142-4 |
0.302 |
|
| 1986 |
Hagenbeek A, Martens ACM. AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML) European Journal of Cancer and Clinical Oncology. 22: 1255-1258. PMID 3469100 DOI: 10.1016/0277-5379(86)90328-7 |
0.371 |
|
| 1986 |
Schultz FW, Martens ACM, Hagenbeek A. Growth kinetics of minimal residual disease in the brown norway rat acute myeloid leukemia Leukemia Research. 10: 104. DOI: 10.1016/0145-2126(86)90162-1 |
0.396 |
|
| 1986 |
Hagenbeek A, Martens ACM. An Immunological Approach to Analyse the Kinetics of Minimal Residual Disease in Acute Leukemia Leukemia Research. 10: 76-85. DOI: 10.1016/0145-2126(86)90119-0 |
0.38 |
|
| 1985 |
Hagenbeek A, Martens ACM. Reinfusion of leukemic cells with the autologous marrow graft: Preclinical studies on lodging and regrowth of leukemia Leukemia Research. 9: 1389-1395. PMID 3908829 DOI: 10.1016/0145-2126(85)90127-4 |
0.418 |
|
| 1985 |
Cardozo BL, Zoetelief H, van Bekkum DW, Zurcher C, Hagenbeek A. Lung damage following bone marrow transplantation: I. The contribution of irradiation. International Journal of Radiation Oncology, Biology, Physics. 11: 907-14. PMID 3886609 DOI: 10.1016/0360-3016(85)90112-9 |
0.354 |
|
| 1985 |
Martens ACM, Hagenbeek A. Detection of minimal disease in acute leukemia using flow cytometry: Studies in a rat model for human acute leukemia Cytometry. 6: 342-347. PMID 3860369 DOI: 10.1002/Cyto.990060411 |
0.354 |
|
| 1985 |
Hagenbeek A, Martens ACM. Detection of minimal residual disease in acute leukemia: possibilities and limitations. European Journal of Cancer and Clinical Oncology. 21: 389-395. PMID 3859413 DOI: 10.1016/0277-5379(85)90139-7 |
0.358 |
|
| 1985 |
Cardozo BL, Hagenbeek A. Interstitial pneumonitis following bone marrow transplantation: pathogenesis and therapeutic considerations. European Journal of Cancer & Clinical Oncology. 21: 43-51. PMID 2982621 DOI: 10.1016/0277-5379(85)90199-3 |
0.372 |
|
| 1985 |
Joosten P, Hagenbeek A, Lowenberg B, Sizoo W. High-dose methotrexate with leucovorin rescue: effectiveness in relapsed hairy cell leukemia. Blood. 66: 241-242. DOI: 10.1182/Blood.V66.1.241.241 |
0.4 |
|
| 1984 |
Nooter K, Sonneveld P, Deurloo J, Oostrum R, Schultz F, Martens A, Hagenbeek A. Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity. Cancer Chemotherapy and Pharmacology. 12: 187-9. PMID 6705136 DOI: 10.1007/Bf00256543 |
0.308 |
|
| 1984 |
Colly LP, Bekkum DWV, Hagenbeek A. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia. Leukemia Research. 8: 953-963. PMID 6595483 DOI: 10.1016/0145-2126(84)90049-3 |
0.321 |
|
| 1984 |
Colly LP, Bekkum DWV, Hagenbeek A. Cell kinetic studies after high dose Ara-C and adriamycin treatment in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia. Leukemia Research. 8: 945-952. PMID 6595482 DOI: 10.1016/0145-2126(84)90048-1 |
0.353 |
|
| 1984 |
Kluin-Nelemans HC, Martens ACM, Löwenberg B, Hagenbeek A. No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557. Leukemia Research. 8: 723-728. PMID 6590937 DOI: 10.1016/0145-2126(84)90020-1 |
0.36 |
|
| 1984 |
Löwenberg B, Abels J, Bekkum DWv, Dzoljic G, Hagenbeek A, Hendriks WDH, Poel Jvd, Sizoo W, Sintnicolaas K, Wagemaker G. Transplantation of non-purified autologous bone marrow in patients with AML in first remission. Cancer. 54: 2840-2843. PMID 6388819 DOI: 10.1002/1097-0142(19841215)54:12<2840::Aid-Cncr2820541204>3.0.Co;2-4 |
0.416 |
|
| 1984 |
Hagenbeek A, Martens ACM. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: Implications for autologous bone marrow transplantation Investigational New Drugs. 2: 237-243. PMID 6381383 DOI: 10.1007/Bf00232358 |
0.336 |
|
| 1984 |
Cardozo BL, Martens ACM, Zurcher C, Hagenbeek A. Secondary tumors after high-dose cyclophosphamide and total-body irradiation followed by bone marrow transplantation in a rat model for human acute myelocytic leukemia (BNML). European Journal of Cancer and Clinical Oncology. 20: 695-698. PMID 6329763 DOI: 10.1016/0277-5379(84)90018-X |
0.347 |
|
| 1984 |
Löwenberg B, Hagenbeek A, Sizoo W, Gast GCD, Verdonck LF, Maraninchi D, Mascret B, Gastaut JA, Sebahoun G, Novakovitch G, Tubiana N, Carcassonne Y. Bone Marrow Transplantation Strategies In Acute Leukaemia The Lancet. 324: 1400-1401. DOI: 10.1016/S0140-6736(84)92094-4 |
0.303 |
|
| 1983 |
Hagenbeek A, Martens ACM. BCG treatment of residual disease in acute leukemia: Studies in a rat model for human acute myelocytic leukemia (BNML) Leukemia Research. 7: 547-555. PMID 6578394 DOI: 10.1016/0145-2126(83)90049-8 |
0.393 |
|
| 1983 |
Hagenbeek A, Sizoo W, Löwenberg B. Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients. Leukemia Research. 7: 443-446. PMID 6350731 DOI: 10.1016/0145-2126(83)90109-1 |
0.402 |
|
| 1982 |
Hagenbeek A, Martens ACM. High-dose cyclophosphamide treatment of acute myelocytic leukemia. Studies in the BNML rat model European Journal of Cancer and Clinical Oncology. 18: 763-769. PMID 6759141 DOI: 10.1016/0277-5379(82)90075-X |
0.396 |
|
| 1981 |
Martens AC, van den Engh GJ, Hagenbeek A. The fluorescence intensity of propidium iodide bound to DNA depends on the concentration of sodium chloride. Cytometry. 2: 24-5. PMID 7273973 DOI: 10.1002/Cyto.990020105 |
0.556 |
|
| 1981 |
Hagenbeek A, Martens ACM. The effect of fractionated versus unfractionated total body irradiation on the growth of the bn acute myelocytic leukemia International Journal of Radiation Oncology Biology Physics. 7: 1075-1079. PMID 7028694 DOI: 10.1016/0360-3016(81)90162-0 |
0.363 |
|
| 1981 |
Hagenbeek A, Martens ACM, Bekkum DWv. Separation of normal hemopoietic stem cells from clonogenic leukemic cells in a rat model for human acute myelocytic leukemia.-I. Velocity sedimentation. Leukemia Research. 5: 421-428. PMID 7026905 DOI: 10.1016/0145-2126(81)90017-5 |
0.37 |
|
| 1981 |
Hagenbeek A, Martens ACM. The proliferative state of normal hemopoietic stem cells during progression of leukemia. Studies in the BN acute myelocytic leukemia (BNML) Leukemia Research. 5: 141-148. PMID 6941052 DOI: 10.1016/0145-2126(81)90072-2 |
0.364 |
|
| 1981 |
Hagenbeek A, Martens ACM. Extracorporeal irradiation of the blood in a rat model for human acute myelocytic leukemia. Increased efficacy after combination with cell mobilization by low-molecular-weight dextran sulfate. Radiation Research. 88: 144-154. DOI: 10.2307/3575759 |
0.342 |
|
| 1981 |
Hagenbeek A, Martens ACM. Extracorporeal irradiation of the blood in a rat model for human acute myelocytic leukemia. Comparative evaluation of three treatment regimens with emphasis on cell compartment analysis Radiation Research. 85: 480. DOI: 10.2307/3575419 |
0.327 |
|
| 1970 |
Ormai S, Hagenbeek A, Bekkum DWV. Lymphocyte-mobilizing agents: Effects of polymethacrylic acid on transplantable lymphoma in rodents European Journal of Cancer. 6: 365-368. PMID 5500703 DOI: 10.1016/0014-2964(70)90033-2 |
0.367 |
|
| Show low-probability matches. |
